In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
October 20th, 2005 | 41 | No |
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8; D01161; Faslodex (TN); Fulvestrant (JAN/USAN/INN)
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AstraZeneca brand of fulvestrant
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 7.96 | -0.35 | -17.51 | 2 | 3 | 0 | 57 | 606.782 | 15 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
ALOGPS_SOLUBILITY | 6.72e-03 g/l | DrugBank-approved |
Patent Database Links | EP1669073; EP1813609; EP1873258; EP1944041; EP1988098; US2005059672; US2005276812; US2006040958; US2006041131; US2006094706; US2006106023; US2006106029; US2006128725; US2006154937; US2007185069; US2007190102; US2007196269; US2007213340; US2007225270; US20 | ChEBI |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
ESR1-1-E | Estrogen Receptor Alpha (cluster #1 Of 5), Eukaryotic | Eukaryotes | 8 | 0.28 | Binding ≤ 10μM |
ESR2-1-E | Estrogen Receptor Beta (cluster #1 Of 4), Eukaryotic | Eukaryotes | 8 | 0.28 | Binding ≤ 10μM |
ESR1-1-E | Estrogen Receptor Alpha (cluster #1 Of 3), Eukaryotic | Eukaryotes | 5 | 0.28 | Functional ≤ 10μM |
ESR2-1-E | Estrogen Receptor Beta (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5 | 0.28 | Functional ≤ 10μM |
Z80224-1-O | MCF7 (Breast Carcinoma Cells) (cluster #1 Of 14), Other | Other | 18 | 0.26 | Functional ≤ 10μM |
Z81170-1-O | LNCaP (Prostate Carcinoma) (cluster #1 Of 5), Other | Other | 18 | 0.26 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
ESR1_HUMAN | P03372 | Estrogen Receptor Alpha, Human | 0.668 | 0.31 | Binding ≤ 1μM |
ESR2_HUMAN | Q92731 | Estrogen Receptor Beta, Human | 0.668 | 0.31 | Binding ≤ 1μM |
ESR1_HUMAN | P03372 | Estrogen Receptor Alpha, Human | 0.668 | 0.31 | Binding ≤ 10μM |
ESR2_HUMAN | Q92731 | Estrogen Receptor Beta, Human | 0.668 | 0.31 | Binding ≤ 10μM |
ESR1_HUMAN | P03372 | Estrogen Receptor Alpha, Human | 0.21 | 0.33 | Functional ≤ 10μM |
ESR2_HUMAN | Q92731 | Estrogen Receptor Beta, Human | 0.21 | 0.33 | Functional ≤ 10μM |
Z81170 | Z81170 | LNCaP (Prostate Carcinoma) | 18 | 0.26 | Functional ≤ 10μM |
Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 0.49 | 0.32 | Functional ≤ 10μM |
Description | Species |
---|---|
Nuclear Receptor transcription pathway | |
Nuclear signaling by ERBB4 |